0
selected
-
1.
Resveratrol and anti-atherogenic effects.
Riccioni, G, Gammone, MA, Tettamanti, G, Bergante, S, Pluchinotta, FR, D'Orazio, N
International journal of food sciences and nutrition. 2015;(6):603-10
Abstract
The role of inflammation and oxidative stress in atherosclerosis development has been increasingly well recognized over the past decade. Inflammation has a significant role at all stages of atherosclerosis, including initiation, progression and plaque formation. Resveratrol is a naturally occurring polyphenolic compound found in grape products, berry fruits and red wine. Its ability to behave therapeutically as a component of red wine has attracted wide attention. Accumulating evidence suggests that it is a highly pleiotropic molecule that modulates numerous targets and molecular functions. Epidemiological studies indicate that the Mediterranean diet, rich in resveratrol, is associated with a reduced risk of atherosclerosis. Resveratrol is believed to decrease circulating low-density lipoprotein cholesterol levels, reduce cardiovascular disease risk; it reduces lipid peroxidation, platelet aggregation and oxidative stress. Resveratrol is considered a safe compound, since no significant toxic effects have been demonstrated after administration of a broad range of concentrations, and an effective anti-atherogenic agent.
-
2.
[From the Point of View of Health Evaluation and Promotion (Ningen Dock) Facilities].
Yamashita, T, Funatsu, K, Kondo, S, Yokoyama, M, Mizuno, K, Nakamura, H
Rinsho byori. The Japanese journal of clinical pathology. 2014;(9):892-4
Abstract
Since the direct method of LDL measurement is easy and convenient, many health evaluation and promotion facilities adopted it without sufficient discussion after specific health checkups started in Japan. For the purpose of reliable, specific health checkup data, we must review the methods and standardization of LDL measurement. I hope that medical societies, the Ministry of Health, Labour and Welfare, and reagent manufacturers will collaborate.
-
3.
[Chronic liver disease and arteriosclerosis].
Mawatari, S, Uto, H, Tsubouchi, H
Nihon rinsho. Japanese journal of clinical medicine. 2011;(1):153-7
Abstract
The liver is the main metabolic organ of the body and is strongly associated with lifestyle-related diseases in which abnormal metabolism of glucose and lipid are the main manifestations. Recently, the prevalence of nonalcoholic fatty liver disease(NAFLD), including nonalcoholic steatohepatitis (NASH), has been increasing due to a higher rates of obesity. It has been reported that the presence of NAFLD/NASH and associated liver dysfunction are predictors for cardiovascular disease. In addition, attention has been paid to the link between chronic hepatitis C and lifestyle-related diseases such as obesity and insulin resistance. Atherosclerosis is an important risk factor for cardiovascular disease and is associated with lifestyle-related diseases. Thus, chronic liver disease seems to be strongly associated with atherosclerosis. Cardiovascular disease induced by atherosclerosis should be attended to along with liver cirrhosis and hepatocellular carcinoma, and medications for lifestyle-related diseases are needed in patients with chronic liver disease.
-
4.
[Lifestyle-related diseases and H. pylori].
Suzuki, H, Matsuzaki, J, Hibi, T
Nihon rinsho. Japanese journal of clinical medicine. 2009;(12):2366-71
Abstract
H. pylori infection elicits a chronic cellular inflammatory response not only in the gastric mucosa, but also in the extra-digestive organs. Indeed, H. pylori infection has been epidemiologically linked to the extra-digestive conditions and diseases. In this article, we review recent progress in our understanding about the relationship between H. pylori infection and lifestyle-related diseases, such as atherosclerosis, diabetes mellitus, obesity, hyperlipidemia, hypertension, and osteoporosis. Although the relationships between all of these diseases and H. pylori infection are still controversial, H. pylori infection may increase the risk for cardiovascular and cerebrovascular diseases, especially when CagA+ cytotoxic strains of H. pylori are present.
-
5.
Atherothrombotic disease and the role of antiplatelet therapy in women.
Grines, C, Cho, L
Journal of women's health (2002). 2008;(1):35-46
Abstract
BACKGROUND Atherothrombosis is associated with significant mortality and morbidity in both men and women. Management of this disease, however, is generally guided by evidence from trials conducted predominantly in men, with few studies focused on women alone. Our objective was to review the characteristics and management of atherothrombotic disease in women, with particular emphasis on the therapeutic role of antiplatelet agents. METHODS Landmark clinical trials and other studies pertaining to atherothrombosis in women (including risk factors, clinical outcomes, and treatment patterns) were obtained through Pubmed and Medline literature research and reviewed. RESULTS Primary prevention studies indicate a clear benefit of antiplatelet therapy in the reduction of cardiovascular events and, in particular, the risk of stroke in women >or=65 years. In men, this benefit is attributable to a reduction in the risk of myocardial infarction (MI). Combination therapies, including aspirin plus dipyridamole or clopidogrel, effectively reduce the risk of recurrent ischemic events in women. However, the effects are not consistent between men and women across studies. Similarly, gender differences exist in the effect of intravenous glycoprotein IIb/IIIa inhibitors plus aspirin on the risk of death or cardiovascular events. CONCLUSIONS The effects of antiplatelet therapy regimens differ between men and women. The mechanisms underlying these differences are still to be elucidated; this report highlights the need for more studies focused on women in order to optimize gender-specific therapy and, therefore, improve clinical outcomes in women with atherothrombosis.
-
6.
Use of vascular ultrasound in clinical trials to evaluate new cardiovascular therapies.
Nash, DT
Journal of the National Medical Association. 2008;(2):222-9
Abstract
Though progress has been made in the fight against cardiovascular disease (CVD), the increasing global prevalence of cardiovascular (CV) risk factors ensures that CVD rates remain high. In order to reduce CVD incidence, a huge effort has been made to uncover additional targets for therapy and novel methods of identifying patients at risk. A low level of high-density-lipoprotein (HDL) cholesterol is recognized as an important independent risk factor for occurrence of a CV event, and new therapies capable of producing effective, clinically relevant increases in this key lipoprotein particle are in development. These therapies will most likely be assessed in comparison with proven CV-risk-reducing therapies such as statin treatment, rather than against a placebo comparator. Inevitably, therefore, clinical end-point trials will increase in both complexity and longevity. Potential efficacy data on new therapies may be revealed sooner by trials using surrogate end points, biomarkers of disease progression known to correlate with clinical events. For novel CV therapies, ultrasound-measured changes in atherosclerosis, such as the change in atheroma burden or plaque volume measured by intravascular ultrasound (IVUS), or ultrasound-measured increase in carotid intima-media thickness (CIMT), may represent useful biomarkers. Both IVUS and CIMT are being widely deployed in trials of new and existing CV therapies to assess their impact on slowing the progression of atherosclerosis, and their use in this regard is the subject of this review.
-
7.
[Life-style-related disorders and atherosclerosis].
Yamada, N
Nihon yakurigaku zasshi. Folia pharmacologica Japonica. 2008;(2):89-91
-
8.
[Hyper-remnant lipoproteinemia].
Doi, H, Matsumura, T, Abe, K
Nihon rinsho. Japanese journal of clinical medicine. 2007;:360-5
-
9.
Lipid-lowering for peripheral arterial disease of the lower limb.
Aung, PP, Maxwell, HG, Jepson, RG, Price, JF, Leng, GC
The Cochrane database of systematic reviews. 2007;(4):CD000123
-
-
Free full text
-
Abstract
BACKGROUND Lipid-lowering therapy is recommended for secondary prevention in people with coronary artery disease. It may also reduce cardiovascular events and/or local disease progression in people with lower limb peripheral arterial disease (PAD). OBJECTIVES To assess the effects of lipid-lowering therapy on all-cause mortality, cardiovascular events and local disease progression in patients with PAD of the lower limb. SEARCH STRATEGY The authors searched The Cochrane Peripheral Vascular Diseases Group's Specialised Register (last searched February 2007) and the Cochrane Central Register of Controlled Trials (CENTRAL) (last searched Issue 2, 2007) for publications describing randomised controlled trials of lipid-lowering therapy in peripheral arterial disease of the lower limb. SELECTION CRITERIA Randomised controlled trials of lipid-lowering therapy in patients with PAD of the lower limb. DATA COLLECTION AND ANALYSIS Three authors independently assessed trial quality and extracted data. MAIN RESULTS Eighteen trials were included, involving a total of 10,049 participants. Trials differed considerably in their inclusion criteria, outcomes measured, and type of lipid-lowering therapy used. Only one trial (PQRST) reported a detrimental effect of active treatment on blood lipid/lipoprotein levels. The pooled results from all eligible trials indicated that lipid-lowering therapy had no statistically significant effect on overall mortality (Odds Ratio (OR) 0.86; 95% Confidence Interval (CI) 0.49 to 1.50) or on total cardiovascular events (OR 0.8; 95% CI 0.59 to 1.09). However, subgroup analysis which excluded PQRST showed that lipid-lowering therapy significantly reduced the risk of total cardiovascular events (OR 0.74; CI 0.55 to 0.98). This was primarily due to a positive effect on total coronary events (OR 0.76; 95% CI 0.67 to 0.87). Greatest evidence of effectiveness came from the use of simvastatin in people with a blood cholesterol ≥ 3.5 mmol/litre (HPS). Pooling of the results from several small trials on a range of different lipid-lowering agents indicated an improvement in total walking distance (Weighted Mean Difference (WMD) 152 m; 95% CI 32.11 to 271.88) and pain-free walking distance (WMD 89.76 m; 95% CI 30.05 to 149.47) but no significant impact on ankle brachial index (WMD 0.04; 95% CI -0.01 to 0.09). AUTHORS' CONCLUSIONS Lipid-lowering therapy is effective in reducing cardiovascular mortality and morbidity in people with PAD. It may also improve local symptoms. Until further evidence on the relative effectiveness of different lipid-lowering agents is available, use of a statin in people with PAD and a blood cholesterol level ≥3.5 mmol/litre is most indicated.
-
10.
[Hormone replacement Up-to-date. Effects of androgen replacement therapy on vascular function and atherosclerosis].
Akishita, M
Clinical calcium. 2007;(9):1385-91
Abstract
It has been postulated that testosterone is atherogenic in contrast to vasoprotective action of estrogen. Recent studies, however, have shown that partial androgen deficiency is associated with cardiovascular disease in the aging male. Although the results of some small-scale studies support the cardioprotective effects of androgen replacement therapy, clinical trials and investigations on the mechanism of action will be required to elucidate the application of androgen replacement therapy. This article illustrates the current concept on the role of testosterone in the cardiovascular system and disease in men.